A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF 3 LOTS OF RESPIRATORY SYNCYTIAL VIRUS (RSV) PREFUSION F SUBUNIT VACCINE IN HEALTHY ADULTS
Latest Information Update: 14 Apr 2023
At a glance
- Drugs Respiratory syncytial virus vaccine Pfizer (Primary)
- Indications Respiratory syncytial virus infections
- Focus Adverse reactions; Pharmacodynamics; Registrational
- Sponsors Pfizer
- 20 May 2022 Status changed from recruiting to completed.
- 04 Mar 2022 Planned primary completion date changed from 10 Jan 2022 to 21 Mar 2022.
- 04 Mar 2022 Status changed from active, no longer recruiting to recruiting.